Pfizer has announced that Patrizia Cavazzoni, M.D., will rejoin the company as Chief Medical Officer and Executive Vice President. In this role, Dr. Cavazzoni will oversee regulatory, pharmacovigilance, safety, epidemiology, medical information, and evidence-generation functions. She will report to Chris Boshoff, M.D., Ph.D., Chief Scientific Officer and President of Pfizer Research & Development. Dr. Cavazzoni succeeds Aida Habtezion, M.D., MSc, FRCPC, AGAF, who is leaving the company to pursue other opportunities. With over 25 years of experience in clinical development, regulatory affairs, and pharmacovigilance, Dr. Cavazzoni has held senior positions in the pharmaceutical industry, including at Pfizer, Eli Lilly, and Sanofi.
Before returning to Pfizer, Dr. Cavazzoni served as Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration, where she played a key role in ensuring the safety and effectiveness of medicines. She earned her medical degree from McGill University and specialized in psychiatry at the University of Ottawa. Her research contributions include work on genetic predictors of bipolar disorder.
